Loading...
Cerebrospinal Fluid Defines SOD1 as a Pharmacodynamic Marker for Antisense Oligonucleotide Therapy
BACKGROUND: Therapies designed to decrease SOD1 are currently in clinical trial for patients with superoxide dismutase (SOD1)-linked Familial Amyotrophic Lateral Sclerosis (ALS), OBJECTIVE: To determine whether SOD1 protein in cerebral spinal fluid (CSF) may be a pharmacodynamic marker and whether S...
Na minha lista:
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
2013
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3812918/ https://ncbi.nlm.nih.gov/pubmed/23147550 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamaneurol.2013.593 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|